Navigation Links
NOVAVAX to Present at Oppenheimer 20th Annual Healthcare Conference
Date:10/29/2009

ROCKVILLE, Md., Oct. 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Oppenheimer 20th Annual Healthcare Conference. Dr. Singhvi's presentation will take place at 3:20 pm local time on November 3, 2009 at the Waldorf=Astoria, New York, NY. Dr. Singhvi will provide an overview of the company's business strategy and research and development progress. A link to the live presentation can be accessed via the Company website at www.novavax.com under the Investors tab. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

About the Oppenheimer 20th Annual Healthcare Conference

The Oppenheimer 20th Annual Healthcare Conference will take place at the Waldorf=Astoria in New York City, November 3-4, 2009. This conference will present a core group of public and private companies who are leaders and pioneers in the pharmaceutical, biotechnology, medical device, healthcare facility, health technology and distribution, provider and service industries. Over 19 years, the Oppenheimer Healthcare Conference has become a highly valuable investor conference in this sector. Through formal company presentations and panels, attendees will gain insight from, and access to, industry leaders.

The Companies participating in this conference will address topical issues such as health reform, Medicare and Medicaid, generic drug regulation, development of new blockbuster pharmaceutical and biotechnology products, product safety and patent issues, cross-border reimportation, Food and Drug Administration policy, managed care, and the current M&A environment.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com

SOURCE Novavax, Inc.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax Announces Poster Presentation at the 47th Annual Meeting of the IDSA
2. Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
3. Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program
4. Novavax CEO to Present at the World Vaccine Congress 2009, Lyon, France
5. Novavax Announces Board of Director Changes
6. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
7. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
8. Novavax Reports Second Quarter 2009 Financial Results
9. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
10. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
11. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... DIEGO , Feb. 22, 2017  PrimeVax Immuno-Oncology, ... will be presenting at the Annual Biocom Global Life ... March 2, at 11:15 AM, at the Torrey Pines ... thankful to the organizers at Biocom who have chosen ... international symposium of biotechnology companies, investors, and clinical researchers," ...
(Date:2/22/2017)... (PRWEB) , ... February 22, ... ... Collaborative (TOPEC), the leading medical education provider of women’s health, primary ... by the Accreditation Council for Continuing Medical Education (ACCME). ACCME’s Accreditation with ...
(Date:2/22/2017)... ... 22, 2017 , ... LabRoots , the leading provider ... world, is pleased to announce the 2nd annual Precision Medicine Virtual Conference. The ... conference focused on the development and advancements in precision medicine. , Precision Medicine ...
(Date:2/22/2017)... Dublin - Research and Markets has ... Market-By Type, By Application, By End User, By Region, By Country: ... ... Market is forecasted to grow at a CAGR of 11.33% during ... crop protection market is driven by the surging demand for less ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice Recognition ... to match it against a stored voiceprint template. ... pitch, cadence, and tone are compared to distinguish ... hardware installation, as most PCs already have a ... transactions. Voice recognition biometrics are most likely to ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
Breaking Biology News(10 mins):